type 2 diabetes
Conditions
Interventions
sitagliptin 50mg/day, alogliptin 25mg/day
Sponsors
Department of Diabetes, Endocrinology and Metabolism, Kawasaki medical scool
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The person who meets the following standards in the outpatients with type 2 diabetes. HbA1c(NGSP) of 7-10%
Exclusion criteria
Exclusion criteria: 1. The patient who taking thiazolidinedione 2. The patient who taking insulin, or the absolute adaptation of insulin therapy 3. The patient who has renal dysfunction (Serum creatinine: male 1.5mg/dl<=, female 1.3mg/dl<=) 4. The patient who has liver dysfunction (ALT and AST: more than two times the upper limit of normal) 5. The patient who has endocrine disease 6. The patient who taking steroid 7. The patient who has malignacy 8. The patient who has severe psychiatric disease 9. The patient under pregnancy or lactation 10. The excessive alcohol ingestion 11. The contraindication of the drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship betweenf blood glucose improvement by DPP-4 inhibitor and the consentration of serum CD26 | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of a correlation factor with Soluble CD26 concentration | — |
Countries
Japan
Contacts
Public ContactMasashi Shimoda
Kawasaki medical school Department of Diabetes, Endocrinology and Metabolism
Outcome results
None listed